EGFR mutation, smoking, and gender in advanced lung adenocarcinoma
| Autor: | Jeng-Sen Tseng, Sung-Liang Yu, Ming Hsun Tsai, Huei-Wen Chen, Chun-Ju Chiang, Chun-Ming Tsai, Gee-Chen Chang, Tsang Wu Liu, Teh Ying Chou, Kang-Yi Su, Sang Hue Yen, Chao-Chi Ho, Chien Hua Tseng, Chih-Liang Wang, Ming Shyan Huang, Ying-Huang Tsai, Tsung-Ying Yang, Hsuan-Yu Chen, Kun-Chieh Chen, Chong-Jen Yu, Jin-Shing Chen, Chih Yi Chen, Kuo-Hsuan Hsu, Jeremy J.W. Chen |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Oncology medicine.medical_specialty Multivariate analysis medicine.medical_treatment overall survival smoking Targeted therapy 03 medical and health sciences 0302 clinical medicine Internal medicine medicine Epidermal growth factor receptor Lung cancer Lung biology business.industry Hazard ratio medicine.disease lung adenocarcinoma Confidence interval epidermal growth factor receptor (EGFR) mutation 030104 developmental biology medicine.anatomical_structure 030220 oncology & carcinogenesis biology.protein Adenocarcinoma business Research Paper |
| Zdroj: | Oncotarget |
| ISSN: | 1949-2553 |
| Popis: | Purpose In the current targeted therapy era, information on the effect of smoking in epidermal growth factor receptor (EGFR)-mutant lung cancer patients is scarce. Results In total, 11,678 adenocarcinoma patients were enrolled. Of these, 33.3% and 91.8% of male and female patients were non-smokers, respectively. An increased amount of smoking (P < 0.001 for trend), fewer smoke-free years (P < 0.001 for trend), and younger age of smoking initiation (P = 0.034 for trend) were all associated with significantly lower EGFR mutation rates. Smokers had a shorter median overall survival (OS) among both EGFR-mutant and EGFR-wild type patients (17.8 vs. 21.1 months, and 7.9 vs. 11.4 months respectively; both P < 0.001). Among patients with EGFR-mutant adenocarcinoma, younger smokers were associated with shorter OS (P = 0.047). In multivariate analysis, female gender was an independent prognostic factor for OS (hazard ratio: 0.86 [95% confidence interval {CI}: 0.80-0.93]; P < 0.001 in the EGFR-mutant group and 0.88 [95% CI: 0.81-0.96]; P = 0.004 in the EGFR-wild type group). Materials and Methods We reviewed the National Lung Cancer database (Taiwan) to assess the impact of smoking on the EGFR mutation rate and survival in advanced lung adenocarcinoma patients during 2011 and 2014 retrospectively. Conclusions Smoking was associated with lower incidence of EGFR mutation rate and reduced OS of advanced lung adenocarcinoma patients in a dose-dependent manner. In addition to EGFR mutation and smoking, gender also plays an important role in survival among these patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|